MARKET

PTE

PTE

PolarityTE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.315
-0.015
-1.13%
Opening 14:41 02/26 EST
OPEN
1.300
PREV CLOSE
1.330
HIGH
1.370
LOW
1.220
VOLUME
3.27M
TURNOVER
--
52 WEEK HIGH
2.380
52 WEEK LOW
0.5530
MARKET CAP
91.03M
P/E (TTM)
-0.7784
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Stella Diagnostics Announces Key Additions to its Board of Directors
SALT LAKE CITY, UT / ACCESSWIRE / February 25, 2021 / . (OTC PINK:JMDP) ("Stella" or "The Company") today announced that it has appointed Peter A. Cohen, Seth Platt, and David Seaburg to its Board of Directors. The three new members have decades of experie...
ACCESSWIRE · 1d ago
What Percentage Of PolarityTE, Inc. (NASDAQ:PTE) Shares Do Insiders Own?
If you want to know who really controls PolarityTE, Inc. ( NASDAQ:PTE ), then you'll have to look at the makeup of its...
Simply Wall St. · 02/19 11:10
BRIEF-Polarityte Says Believes It Remains On Track To File IND For SkinTE In H2 2021
reuters.com · 02/10 13:17
PolarityTE Provides Corporate Update
BusinessWire - BZX · 02/10 13:00
The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 3)
Benzinga · 02/04 12:21
PolarityTE Receives Allowance for Additional U.S. Patent
PolarityTE, Inc. (Nasdaq: PTE) is pleased to report the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application No....
BusinessWire - BZX · 02/04 04:06
BRIEF-PolarityTE Receives Allowance For Additional U.S. Patent
reuters.com · 02/03 21:39
PolarityTE Receives Allowance for Additional U.S. Patent
Business Wire · 02/03 21:15
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PTE. Analyze the recent business situations of PolarityTE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PTE stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 120
Institutional Holdings: 11.77M
% Owned: 17.01%
Shares Outstanding: 69.22M
TypeInstitutionsShares
Increased
12
866.87K
New
18
2.52M
Decreased
12
877.71K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.53%
Pharmaceuticals & Medical Research
-0.87%
Key Executives
Chairman/Independent Director
Peter Cohen
President/Chief Operating Officer
Richard Hague
Chief Executive Officer/Director
David Seaburg
Chief Financial Officer
Jacob Patterson
Executive Vice President/General Counsel/Secretary
Cameron Hoyler
Director
Chris Nolet
Vice President
Sharon Whalen
Director
Jessica Shen
Director
Jay Hood
Independent Director
Minnie Baylor-Henry
Independent Director
Willie Bogan
Independent Director
Jeff Dyer
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
01/04/2016
Dividend USD 0.33550232
01/19/2016
About PTE
PolarityTE, Inc., formerly Majesco Entertainment Company, is the owner of patent applications and know-how related to regenerative medicine and tissue engineering, as well as software applications used in diagnosis and treatment related to regenerative medicine. The Company seeks to develop and obtain regulatory approval for technology that will utilize a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. The Company's PolarityTE platform simplifies regeneration and allows cells to function naturally. The platform can be applied across all cells, tissues and composite structures. The Company focuses on various products, including SkinTE, OsteoTE, AngioTE, MyoTE, CartTE, AdiposeTE and NeuralTE. The Company, through SkinTE, is focused on supplying an autologous construct to regenerate a patient’s skin due to a variety of injuries and conditions.

Webull offers kinds of Polarityte Inc stock information, including NASDAQ:PTE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTE stock methods without spending real money on the virtual paper trading platform.